Aisling Capital
Aisling Capital believes the next decade will be marked by a revolution in healthcare driven by new therapeutics generated by
Business Model:
Revenue: $15.1M
Employees: 2-10
Rankings
Industries / Tags:
Detailed Aisling Capital Information
Geographic Data
Address: 888 7th Ave
City: New York
State: NY
Zip: 10106
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$423M
Social
Twitter
Linkedin
Crunchbase
Metrics
2,323,328Website Global Rank
8,065Website Monthly Traffic
Twitter Followers
Description
Aisling Capital believes the next decade will be marked by a revolution in healthcare driven by new therapeutics generated by biotechnology. The completion of the human genome has given scientists new insights into the causes of human disease. These insights, combined with the past 20 years of developments in the biotechnology industry, are leading to rapid expansion of novel approaches toward the diagnosis, prevention, and treatment of life-threatening illnesses. These advances have led to an ever-increasing demand for capital to complete the development and commercialization of new therapeutics. Our goal is to support the leading global healthcare companies that are building on these technical and medical breakthroughs to commercialize new healthcare products.
Contact Phone:
+12126516380
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 4/2015 | Spirox | Series B | 18.5M |
| 10/2013 | LENSAR, Inc. | Debt | 60M |
| 10/2013 | LENSAR, Inc. | Equity | 27M |
| 3/2012 | LENSAR, Inc. | Venture Round | 24M |
| 10/2009 | Xanodyne | Venture Round | 0 |
| 3/2016 | Spirox | Series C | 45M |
| 7/2007 | Cempra | Series B | 0 |
| 9/2018 | Atreca | Series C | 125M |
| 10/2013 | Loxo Oncology | Series A | 33M |
| 4/2021 | Antios Therapeutics | Series B | 0 |
| 7/2018 | Ajax Health | Series B | 120M |
| 11/2012 | Ambit Biosciences | Venture Round | 0 |
| 3/2017 | Promentis Pharmaceuticals | Series C | 26M |
| 2/2015 | Agile Therapeutics | Post-IPO Equity | 0 |
| 7/2015 | ViewRay | Post-IPO Equity | 0 |
| 6/2010 | Zeltiq Aesthetics | Series D | 25M |
| 2/2023 | Garuda Therapeutics | Series B | 0 |
| 6/2016 | Miramar Labs | Venture Round | - |
| 1/2021 | Biomea Fusion | Series A | 56M |
| 11/2020 | Elevation Oncology | Series B | 65M |
| 8/2011 | T2 Biosystems | Series D | 0 |
| 9/2017 | GTx | Post-IPO Equity | 48.5M |
| 6/2016 | Verona Pharma | Post-IPO Equity | 65.6M |
| 4/2010 | Aragon Pharmaceuticals, Inc. | Series B | 22M |
| 11/2015 | ObsEva | Series B | 60M |
| 10/2013 | Seragon Pharmaceuticals | Series A | 30M |
| 10/2018 | Earlens | Series D | 0 |
| 2/2018 | Avrobio | Series B | 60M |
| 2/2012 | CeNeRx BioPharma | Series D | 4.6M |
| 7/2020 | Verona Pharma | Private Placement | 200M |
| 10/2014 | Miramar Labs | Series D | 26M |
| 7/2017 | VYNE Therapeutics | Series C | 50.5M |
| 4/2007 | Bioenvision | Venture Round | 7.4M |
| 2/2020 | Spruce Biosciences | Series B | 88M |
| 3/2012 | Cytos | Post-IPO Equity | 40M |
| 4/2019 | Poseida Therapeutics | Series C | 0 |
| 4/2004 | Cardiokine | Series A | 37M |
| 7/2012 | Agile Therapeutics | Series C | 0 |
| 1/2016 | Syros Pharmaceuticals | Series C | 40M |
| 3/2015 | Aimmune Therapeutics | Series B | 80M |
| 4/2013 | Esperion | Venture Round | 33M |
| 9/2022 | Forge Biologics | Series C | 0 |
| 7/2013 | TRIA Beauty | Private Equity Round | 0 |
| 11/2021 | Antios Therapeutics | Series B | 0 |
| 3/2015 | Cynapsus Therapeutics | Venture Round | 16.6M |
| 7/2008 | TRIA Beauty | Series E | 30M |
| 6/2017 | Earlens | Series C | 0 |
| 10/2012 | Aragon Pharmaceuticals, Inc. | Series D | 50M |
| 2/2011 | TRIA Beauty | Venture Round | 26.3M |
| 10/2012 | TRIA Beauty | Venture Round | 7.5M |
| 5/2013 | ViewRay | Venture Round | 15M |
| 9/2021 | Garuda Therapeutics | Series A | 72M |
| 4/2019 | Ajax Health | Series C | 85M |
| 4/2016 | PowerVision | Series D | 10M |
| 10/2019 | Nuvation Bio | Series A | 275M |
| 1/2011 | NextWave Pharmaceuticals | Series C | 45M |
| 10/2002 | Oculex Pharmaceuticals | Series B | 50M |
| 1/2015 | LENSAR, Inc. | Private Equity Round | 16M |
| 1/2019 | BridgeBio Pharma | Equity | 299.2M |
| 6/2009 | Cempra | Series C | 46M |
| 6/2016 | Aclaris Therapeutics | Post-IPO Equity | 20M |
| 4/2006 | Cempra | Series A | 22M |
| 12/2016 | Prolacta Bioscience | Venture Round | 0 |
| 3/2013 | T2 Biosystems | Series E | 40M |
| 10/2014 | Syros Pharmaceuticals | Series B | 53M |
| 5/2002 | Advion Inc. | Series B | 15M |
| 7/2013 | Versartis | Series C | 0 |
| 9/2020 | Monte Rosa Therapeutics | Series B | 0 |
| 8/2014 | Dermira | Series C | 51M |
| 1/2008 | ViewRay | Series B | 25M |
| 5/2014 | Loxo Oncology | Series B | 24M |
| 6/2016 | Earlens | Series C | 0 |
| 3/2021 | Monte Rosa Therapeutics | Series C | 0 |
| 1/2013 | Versartis | Series C | 0 |
| 12/2013 | ViewRay | Venture Round | 0 |
| 3/2012 | ViewRay | Series C | 45M |
| 12/2007 | Topaz Pharmaceuticals Inc | Series A | 20M |
| 2/2011 | Pharmaron | Series C | 40M |
| 10/2020 | Talaris Therapeutics | Series B | 0 |
| 10/2009 | Asensus Surgical | Post-IPO Equity | 0 |
| 2/2014 | Versartis | Series E | 55M |
| 4/2012 | PreCision Dermatology | Venture Round | 29.4M |
| 6/2022 | Dren Bio | Series B | 0 |
| 6/2016 | F2G | Series E | 60M |
| 6/2019 | Ajax Health | Series C | 15M |
| 10/2007 | Paratek Pharmaceuticals | Post-IPO Equity | 40M |
| 2/2015 | Cidara Therapeutics | Series B | 42M |
| 4/2018 | Eidos Therapeutics | Series B | 0 |
| 9/2011 | ViewRay | Debt Financing | 10M |
| 8/2010 | ViewRay | Series C | 20M |
| 2/2012 | ADMA Biologics | Venture Round | 0 |
| 7/2007 | Xanodyne | Series A | 25M |
| 4/2014 | Earlens | Series B | 40M |
| 4/2018 | Zosano Pharma | Post-IPO Equity | 50M |
| 8/2012 | Intercept Pharmaceuticals | Series C | 30M |
| 11/2017 | Arcus Biosciences | Series C | 107M |
| 4/2007 | Sirion Therapeutics | Series B | 45M |
| 11/2016 | Biohaven Pharmaceutical | Venture Round | 80M |
| 1/2017 | Ajax Health | Series A | 95M |
| 4/2007 | Natural Dentist | Series B | 13.2M |
| 7/2021 | Wugen | Series B | 0 |
| 12/2020 | Reneo Pharmaceuticals | Series B | 0 |
| 9/2017 | BridgeBio Pharma | Series C | 135M |
| 3/2016 | Zavante Therapeutics | Series A | 45M |
| 7/2020 | Elevation Oncology | Series A | 32.5M |
| 6/2014 | Cidara Therapeutics | Series A | 32M |
| 7/2014 | Paratek Pharmaceuticals | Post-IPO Debt | 93M |
| 1/2002 | Allos Therapeutics | Private Equity Round | - |
| 10/2013 | Versartis | Series D | 0 |
| 6/2014 | PowerVision | Series D | 30M |
| 1/2012 | Roka Bioscience | Series D | 47.5M |
| 6/2007 | BioRelix | Series A | 25.8M |
| 9/2008 | Bridge Pharmaceuticals | Series B | 53.3M |
| 5/2008 | Esperion | Series A | 22.8M |
| 6/2022 | Dren Bio | Series B | 0 |
| 11/2021 | Antios Therapeutics | Series B | 0 |
| 9/2021 | Garuda Therapeutics | Series A | 0 |
| 7/2021 | Wugen | Series B | 0 |
| 4/2021 | Antios Therapeutics | Series B | 0 |
| 3/2021 | Monte Rosa Therapeutics | Series C | 0 |
| 1/2021 | Biomea Fusion | Series A | 0 |
| 12/2020 | Reneo Pharmaceuticals | Series B | 0 |
| 11/2020 | Elevation Oncology | Series B | 0 |
| 10/2020 | Talaris Therapeutics | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
